{
    "root": "24fdbe72-a9c4-6144-e063-6394a90ac10d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Prochlorperazine Edisylate",
    "value": "20241221",
    "ingredients": [
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM TARTRATE DIHYDRATE",
            "code": "DIA7C37AOW",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_132950"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32112"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "PROCHLORPERAZINE EDISYLATE",
            "code": "PG20W5VQZS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232994"
        }
    ],
    "indications": {
        "text": "control severe nausea vomiting . treatment schizophrenia . prochlorperazine shown effective management behavioral complications patients mental retardation .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "mental retardation (DOID:1059)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1059"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "note injection : intramuscular , inject deeply upper , outer quadrant buttock . subcutaneous advisable local irritation . stability solution protected light . slight yellowish discoloration alter potency . markedly discolored , solution discarded . compatibility recommended prochlorperazine edisylate injection mixed agents syringe . adults ( children 's , . ) increased gradually debilitated emaciated patients . elderly patients general , dosages lower range sufficient elderly patients . since appear susceptible hypotension neuromuscular , patients observed closely . tailored individual , response carefully monitored , adjusted accordingly . increased gradually elderly patients . control severe nausea vomiting adjust response individual . begin lowest recommended . im initially 5 mg 10 mg ( 1 2 ml ) injected deeply upper , outer quadrant buttock . necessary , repeat every 3 4 hours . total im exceed 40 mg per day . iv 2.5 mg 10 mg ( 0.5 2 ml ) slow iv injection infusion rate exceed 5 mg per minute . prochlorperazine edisylate injection may administered either undiluted diluted isotonic solution . single dose exceed 10 mg ; total iv exceed 40 mg per day . administered iv , bolus injection . hypotension possibility given iv injection infusion . subcutaneous advisable local irritation . adult surgery ( severe nausea vomiting ) total parenteral exceed 40 mg per day . hypotension possibility given iv injection infusion . im 5 mg 10 mg ( 1 2 ml ) 1 2 hours induction anesthesia ( repeat 30 minutes , necessary ) , control acute symptoms surgery ( repeat necessary ) . iv 5 mg 10 mg ( 1 2 ml ) slow iv injection infusion 15 30 minutes induction anesthesia , control acute symptoms surgery . repeat necessary . prochlorperazine may administered either undiluted diluted isotonic solution , single dose exceed 10 mg. rate exceed 5 mg per minute . administered iv , bolus injection . adult psychiatric disorders adjust response individual according severity condition . begin lowest recommended dose . although response ordinarily seen within day two , longer treatment usually required maximal improvement seen . im immediate control adult schizophrenic patients severe symptomatology , inject initial dose 10 mg 20 mg ( 2 4 ml ) deeply upper , outer quadrant buttock . many patients respond shortly first injection . necessary , however , repeat initial dose every 2 4 hours ( , resistant cases , every hour ) gain control patient . 3 4 doses seldom necessary . control achieved , switch patient oral form level higher . , rare cases , parenteral therapy needed prolonged period , give 10 mg 20 mg ( 2 4 ml ) every 4 6 hours . pain irritation site injection seldom occurred . subcutaneous advisable local irritation . children pediatric surgery children seem prone develop extrapyramidal , even moderate doses . therefore , lowest effective . tell parents exceed prescribed , since possibility increases rises . occasionally patient may react signs restlessness excitement ; occurs , administer additional doses . take particular precaution administering children acute illnesses dehydration ( dystonia ) . severe nausea vomiting children prochlorperazine used pediatric patients 20 pounds weight two years age . used conditions children 's dosages established . frequency adjusted according severity symptoms response patient . duration activity following intramuscular may last 12 hours . subsequent doses may given route necessary . im calculate dose basis 0.06 mg per lb body weight ; give deep im injection . control usually obtained one dose . children schizophrenia im ages 12 , calculate dose basis 0.06 mg prochlorperazine per lb body weight ; give deep im injection . control usually obtained one dose . control achieved , switch patient oral form level higher . parenteral products inspected visually particulate matter discoloration prior , whenever solution container permit .",
        "doid_entities": [
            {
                "text": "dystonia (DOID:543)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_543"
            },
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "prochlorperazine edisylate injection , usp 5 mg/ml colorless slightly yellowish solution . prochlorperazine edisylate injection , usp supplied follows : ndc 72266-204-10 2 ml ( 10 mg ) multiple-dose vials ( ndc 72266-204-01 ) packages 10. storage protect light . store box ready . discard markedly discolored . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . distributed : fosun pharma usa inc. princeton , nj 08540 december 2024 1313000847-05",
    "adverseReactions": "patients known hypersensitivity phenothiazines . comatose states presence large amounts central nervous system depressants ( alcohol , barbiturates , narcotics , etc . ) . pediatric surgery . pediatric patients 2 years age 20 lbs . children conditions established .",
    "indications_original": "To control severe nausea and vomiting. For the treatment of schizophrenia.\n       \n \n  Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.",
    "contraindications_original": "NOTE ON INJECTION: For intramuscular administration, inject deeply into the upper, outer quadrant of the buttock.\n       \n \n  \n                     \n                     \n                     Subcutaneous administration is not advisable because of local irritation.\u00a0\n        \n  \n   \n                        \n                     \n                     \n                     Stability\n                     This solution should be protected from light. Slight yellowish discoloration will not alter potency. If markedly discolored, solution should be discarded.\n       \n \n  \n                     \n                     \n                     Compatibility\n                     It is recommended that Prochlorperazine Edisylate Injection not be mixed with other agents in the syringe.\n       \n \n  \n                     \n                     \n                     Adults\n                     (For children's dosage and administration, see below.) Dosage should be increased more gradually in debilitated or emaciated patients.\n       \n \n  \n                     \n                     ELDERLY PATIENTS\n       \n \n  In general, dosages in the lower range are sufficient for most elderly patients. Since they appear to be more susceptible to hypotension and neuromuscular reactions, such patients should be observed closely. Dosage should be tailored to the individual, response carefully monitored, and dosage adjusted accordingly. Dosage should be increased more gradually in elderly patients.\n       \n \n  \n                     TO CONTROL SEVERE NAUSEA AND VOMITING\n       \n \n  \n                     \n                     Adjust dosage to the response of the individual. Begin with lowest recommended dosage.\n       \n \n  \n                     \n                     \n                     IM\u00a0\u00a0\n       \n \n  Dosage\n                     Initially 5 mg to 10 mg (1 to 2 mL) injected \n       \n \n  deeply into the upper, outer quadrant of the buttock. If necessary, repeat every 3 or 4 hours. Total IM dosage should not exceed 40 mg per day.\n       \n \n  \n                     \n                     \n                     IV Dosage\n                     2.5 mg to 10 mg (0.5 to 2 mL) by slow IV injection or infusion at a rate not to exceed 5 mg per minute. Prochlorperazine Edisylate Injection may be administered either undiluted or diluted in isotonic solution. A single dose of the drug should not exceed 10 mg; total IV dosage should not exceed 40 mg per day. When administered IV, do not use bolus injection. Hypotension is a possibility if the drug is given by IV injection or infusion.\n       \n \n  \n                     \n                     \n                     Subcutaneous administration is not advisable because of local irritation.\n        \n  \n   \n                        \n                     \n                     ADULT SURGERY (FOR SEVERE NAUSEA AND VOMITING)\n       \n \n  Total parenteral dosage should not exceed 40 mg per day. Hypotension is a possibility if the drug is given by IV injection or infusion.\n       \n \n  \n                     \n                     \n                     IM Dosage\n                     \n                     5 mg to 10 mg (1 to 2 mL) 1 to 2 hours before induction of anesthesia (repeat once in 30 minutes, if necessary), or to control acute symptoms during and after surgery (repeat once if necessary).\n        \n  \n   \n                        \n                     \n                     \n                     IV Dosage\n                     \n                     5 mg to 10 mg (1 to 2 mL) as a slow IV injection or infusion 15 to 30 minutes before induction of anesthesia,\u00a0 or to control acute symptoms during or after surgery. Repeat once if necessary. Prochlorperazine may be administered either undiluted or diluted in isotonic solution, but a single dose of the drug should not exceed 10 mg. The rate of administration should not exceed 5 mg per minute. When administered IV, do not use bolus injection.\n                     \n                     \n                     IN ADULT PSYCHIATRIC DISORDERS\n       \n \n  Adjust dosage to the response of the individual and according to the severity of the condition. Begin with the lowest recommended dose. Although response ordinarily is seen within a day or two, longer treatment is usually required before maximal improvement is seen.\n       \n \n  \n                     \n                     \n                     IM Dosage\u00a0\n                     For immediate control of adult schizophrenic patients with severe symptomatology, inject an initial dose of 10 mg to 20 mg (2 to 4 mL) \n       \n \n  deeply into the upper, outer quadrant of the buttock. Many patients respond shortly after the first injection. If necessary, however, repeat the initial dose every 2 to 4 hours (or, in resistant cases, every hour) to gain control of the patient. More than 3 or 4 doses are seldom necessary. After control is achieved, switch patient to an oral form of the drug at the same dosage level or higher. If, in rare cases, parenteral therapy is needed for a prolonged period, give 10 mg to 20 mg (2 to 4 mL) every 4 to 6 hours. Pain and irritation at the site of injection have seldom occurred.\n      \n\n \n                  \n                  \n                  \n                  \n                  \n                  \n                     Subcutaneous administration is not advisable because of local irritation.\u00a0\n        \n  \n   \n                        \n                     \n                     \n                     Children\n                     \n                     DO NOT USE IN PEDIATRIC SURGERY\n                     Children seem more prone to develop extrapyramidal reactions, even on moderate doses. Therefore, use lowest effective dosage. Tell parents not to exceed prescribed dosage, since the possibility of adverse reactions increases as dosage rises.\n       \n \n  \n                     \n                     Occasionally the patient may react to the drug with signs of restlessness and excitement; if this occurs, do not administer additional doses. Take particular precaution in administering the drug to children with acute illnesses or dehydration (see under PRECAUTIONS and Dystonia).\n       \n \n  \n                     \n                     SEVERE NAUSEA AND VOMITING IN CHILDREN\n       \n \n  \n                     Prochlorperazine should not be used in pediatric patients under 20 pounds in weight or two years of age. It should not be used in conditions for which children's dosages have not been established. Dosage and frequency of administration should be adjusted according to the severity of the symptoms and the response of the patient. The duration of activity following intramuscular administration may last up to 12 hours. Subsequent doses may be given by the same route if necessary.\n      \n\n \n                  \n                  \n                  \n                  \n                  \n                     IM Dosage\n                     Calculate each dose on the basis of 0.06 mg of the drug per\n       \n \n   lb of body weight; give by deep IM injection. Control is usually obtained with one dose.\n       \n \n  \n                     \n                     CHILDREN WITH SCHIZOPHRENIA\n       \n \n  IM Dosage\u00a0\n       \n \n  For ages under 12, calculate each dose on the basis of 0.06 mg of prochlorperazine per\n       \n \n   lb of body weight; give by deep IM injection. Control is usually obtained with one dose. After control is achieved, switch the patient to an oral form of the drug at the same dosage level or higher.\n       \n \n  \n                     \n                     \n                     Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.",
    "warningsAndPrecautions_original": "Prochlorperazine Edisylate Injection, USP 5 mg/mL is a colorless to slightly yellowish solution. Prochlorperazine Edisylate Injection, USP is supplied as follows:\n                  \n                  \n                     \n                        \n                           \n                              NDC 72266-204-10\n    \n                           \n                              2 mL (10 mg) Multiple-Dose Vials (NDC 72266-204-01) in packages of 10.\n                           \n                        \n                     \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                     Storage\n                     \n                     \n                     PROTECT FROM LIGHT. Store in the box until ready to use. Discard if markedly discolored.\n  \n                     \n                     \n                     \n                     Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                     \n                     \n                     \n                     Distributed by:\n                     \nFosun Pharma USA Inc.\n  \nPrinceton, NJ 08540\n \n                  December 2024\n  \n1313000847-05",
    "adverseReactions_original": "Do not use in patients with known hypersensitivity to phenothiazines.\n       \n \n  Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.).\n      \n\n \n                  Do not use in pediatric surgery.\u00a0\n                  Do not use in pediatric patients under 2 years of age or under 20 lbs. Do not use in children for conditions for which dosage has not been established.",
    "drug": [
        {
            "name": "Prochlorperazine Edisylate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232994"
        }
    ]
}